Retinal vein occlusion (RVO) is one of the most common retinal vascular diseases.1–3 Retinal vein occlusion is often accompanied by macular edema (ME) and concomitant visual disturbances.1 The ME associated with RVO can be ameliorated using antivascular endothelial growth factor (VEGF) treatments.4–7 However, blockade of VEGF does not act on thrombus formation in the affected retinal veins, and the ME can recur if an intravitreal level of the anti-VEGF agent is decreased. This evidence concerns the gene VEGFA and macular retinal edema.